Drug Type Small molecule drug |
Synonyms 普卢格列汀, DBPR 108, DBPR-108 |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC16H25FN4O2 |
InChIKeyVQKSCYBKUIDZEI-STQMWFEESA-N |
CAS Registry1186426-66-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | NDA/BLA | CN | 26 Apr 2023 | |
Renal Insufficiency | Phase 1 | CN | 07 Jun 2021 | |
Hepatic Insufficiency | Phase 1 | CN | 04 Jun 2021 | |
Diabetes Mellitus | Phase 1 | TW | 22 Nov 2012 |
NCT04218734 (NEWS) Manual | Phase 3 | 1,000 | mvuqtwifvc(ejkskfqirn) = DBPR108片组显著优于安慰剂组 tslbjssvgb (wqndexzbtg ) | Positive | 22 Aug 2022 | ||
Metformin+Placebo | |||||||
Phase 1 | 32 | placebo+DBPR108 (Placebo) | plsdyaklam(modagfpgbn) = wnbbjtwyuw tzehjwoglc (vmgotrcgie, jyxqtvwoou - efvixrhdaj) View more | - | 28 Aug 2014 | ||
(DBPR108 25 mg) | plsdyaklam(modagfpgbn) = ifidjrbfst tzehjwoglc (vmgotrcgie, nrkhaxgfxe - abzfbeznpx) View more |